From: Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Target | Clinical trial identifier | Blockade agent | Phase | Patient population | Design | Study start date | Current stage |
---|---|---|---|---|---|---|---|
PD-1 | NCT02550249 | Nivolumab | II | Primary and recurrent GBM | Preoperative neoadjuvant | June 2015 | Recruiting participants |
NCT02423343 | Nivolumab | I/II | Recurrent or refractory NSCLC HCC GBM | Combination with galunisertib | October 2015 | Recruiting participants | |
NCT02017717 (CheckMate 143) | Nivolumab | III | Recurrent GBM | Alone or in combination with the IPI Compared to bevacizumab | January 2014 | Ongoing | |
NCT02311920 | Nivolumab | I | Primary GBM | IPI and/or NIVO in combination with temozolomide | April 2015 | Recruiting participants | |
NCT02337491 | Pembrolizumab | II | Recurrent GBM | With or without bevacizumab | February 2015 | Ongoing | |
NCT02311582 | Pembrolizumab | I/II | Recurrent GBM | Combination with MRI-guided laser ablation | August 2015 | Recruiting participants | |
NCT01952769 | Pidilizumab | I/II | DIPG and recurrent GBM | Alone | February 2014 | Recruiting participants | |
PD-L1 | NCT02336165 | MEDI4736 | II | Primary and recurrent GBM | Combination with radiotherapy and bevacizumab | February 2015 | Recruiting participants |
NCT01375842 | MPDL3280A | I | Solid tumors (include GBM) | Alone | June 2011 | Recruiting participants |